TABLE 2.
Summarized Spearman's rank‐order correlations between PRO‐CTCAE items and EORTC QLQ‐C30 domains
| All patients N = 78 | ||||
|---|---|---|---|---|
| Very strong (0.8‐1) | Strong (0.6‐0.79) | Moderate (0.4‐0.59) | Weak (0.2‐0.39) | Very weak (0‐0.19) |
| Anxiety F (−0.603) | Abdominal pain I (−0.481) | Blurred vision S (−0.320) | Change in urine colour P (−0.197) | |
| Concentration S (−0.704) | Decreased appetite I (−0.408) | Chills S (−0.205) | Constipation S (−0.079) | |
| Discouraged F (−0.659) | Dizziness S (−0.496) | Decreased libido S (−0.280) | Cough S (−0.110) | |
| Fatigue S (−0.659) | Muscle pain I (−0.459) | Difficulty swallowing S (−0.270) | Diarrhea F (−0.133) | |
| Memory S (−0.784) | Nausea F (−0.412) | Dry mouth S (−0.386) | Hair loss A (−0.144) | |
| Sad F (−0.711) | Pain I (−0.512) | Dry skin S (−0.251) | Headache I (−0.169) | |
| Shortness of breath I (−0.572) | Heart palpitations F (−0.266) | Heartburn F (−0.197) | ||
| Hives P (−0.267) | Itching S (−0.190) | |||
| Hot flashes F (−0.236) | Mouth/throat sores I (−0.170) | |||
| Increased sweating F (−0.219) | Pain and swelling at injection site P (−0.004) | |||
| Insomnia I (−0.321) | Painful urination S (−0.169) | |||
| Joint pain I (−0.363) | Ringing in ears S (−0.108) | |||
| Numbness & tingling I (−0.286) | Urinary frequency I (−0.131) | |||
| Rash P (−0.283) | Urinary incontinence F (−0.053) | |||
| Swelling of arms or legs I (−0.274) | Urinary urgency I (−0.091) | |||
| Taste changes S (−0.275) | ||||
| Vomiting F (−0.234) | ||||
| Patients with locally advanced disease N = 26 | ||||
| Anxiety F (−0.642) | Abdominal pain I (−0.456) | Blurred vision I (−0.301) | Cough S (−0.110) | |
| Concentration S (−0.715) | Decreased appetite S (−0.500) | Change in urine color P (−0.357) | Diarrhea F (−0.155) | |
| Discouraged F (−0.605) | Dizziness I (−0.483) | Chills S (−0.232) | Itching S (−0.158) | |
| Memory S (−0.758) | Dry mouth S (−0.429) | Constipation S (−0.344) | Mouth/throat sores I (−0.097) | |
| Sad F (−0.621) | Fatigue I (−0.557) | Decreased libido S (−0.200) | Numbness & tingling I (−0.183) | |
| Heart palpitations S (−0.404) | Difficulty swallowing S (−0.329) | Pain and swelling at injection site P (−0.096) | ||
| Nausea F (−0.545) | Dry skin S (−0.256) | Painful urination S (0.106) | ||
| Pain I (−0.514) | Hair loss A (−0.278) | Urinary frequency I (−0.178) | ||
| Shortness of breath I (−0.528) | Headache I (−0.382) | Urinary incontinence F (0.088) | ||
| Taste changes S (−0.487) | Heartburn F (−0.430) | Urinary urgency I (−0.177) | ||
| Hives P (−0.267) | Vomiting F (−0.180) | |||
| Hot flashes F (−0.242) | ||||
| Increased sweating F (−0.257) | ||||
| Insomnia I (−0.335) | ||||
| Joint pain I (−0.354) | ||||
| Muscle pain I (−0.419) | ||||
| Rash P (−0.218) | ||||
| Ringing in ears S (−0.322) | ||||
| Swelling of arms or legs S (−0.206) | ||||
| Patients with metastatic disease N = 52 | ||||
| Concentration S (−0.707) | Abdominal pain I (−0.483) | Blurred vision S (−0.369) | Constipation S (−0.082) | |
| Discouraged F (−0.678) | Anxiety F (−0.577) | Change in urine color P (−0.339) | Cough S (−0.110) | |
| Fatigue S (−0.695) | Decreased appetite S (−0.404) | Chills S (−0.233) | Hair loss A (−0.110) | |
| Memory S (−0.799) | Decreased libido S (−0.443) | Diarrhea F (−0.283) | Headache S (−0.086) | |
| Sad F (−0.751) | Dizziness S (−0.547) | Difficulty swallowing S (−0.312) | Hives P (−0.194) | |
| Dry mouth S (−0.415) | Dry skin S (−0.305) | Painful urination S (0.108) | ||
| Pain F (−0.512) | Heartburn F (−0.245) | Ringing in ears S (−0.057) | ||
| Shortness of breath I (−0.575) | Heart palpitations S (−0.236) | Urinary frequency I (−0.178) | ||
| Hot flashes F (−0.269) | Urinary incontinence I (−0.128) | |||
| Increased sweating F (−0.236) | Urinary urgency I (−0.113) | |||
| Insomnia I (−0.361) | ||||
| Itching S (−0.259) | ||||
| Joint pain I (−0.265) | ||||
| Mouth/throat sores S (−0.295) | ||||
| Muscle pain S (−0.409) | ||||
| Nausea F (−0.364) | ||||
| Numbness & tingling I (−0.288) | ||||
| Pain and swelling at injection site P (−0.214) | ||||
| Rash P (−0.292) | ||||
| Swelling of arms or legs S (−0.293) | ||||
| Taste changes S (−0.210) | ||||
| Vomiting F (−0.276) | ||||
PRO‐CTCAE items were grouped in the above groups very weak, weak, moderate, strong, very strong if one or more item corresponded accordingly to the expected quality of life domain. Values in (parentheses): Rs correlation coefficient. F: frequency, S: severity, I: interference. Green color indicates agreement across all groups.